Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate.. Atara ...

Atara Biotherapeutics Announces Pricing of $16 Million Offering. THOUSAND OAKS, Calif., May 15, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its ...

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and ...

Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.

Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after ...

A high-level overview of Atara Biotherapeutics, Inc. (ATRA) stock. View (ATRA) real-time stock price, chart, news, analysis, analyst reviews and more.

This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of October 1, 2024 ...

Atara Biotherapeutics’ results from the phase 2 BOLD study are expected in October of 2023. Click here to read why ATRA stock is a Strong Buy.

Atara Biotherapeutics' allogeneic Epstein-Barr virus-positive (EBV) T-cell therapy tabelecleucel snagged a world-first approval in Europe, assuming the commercial moniker Ebvallo.

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) shares are trading lower after the company said that primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple ...

Atara had $331.3 million in cash and equivalents on hand as of June 30, compared to $301.8 million at the end of March. The bump is thanks to the sale of the biotech’s ATOM facility that ...

It wasn't just Atara making news at CHMP this week. Regeneron has secured a positive opinion for Libtayo for the treatment of cervical cancer. Already approved in Europe and the U.S for basal cell ...